Simulations Plus: Buying On Long-Term Silico Drug-Development
Source: SeekingAlpha
2025-12-02 21:41:59 ET
...
Read the full article on Seeking Alpha
For further details see:
Simulations Plus: Buying On Long-Term Silico Drug-Development
Simulations Plus Inc.
NASDAQ: SLP
SLP Trading
-0.16% G/L:
$12.22 Last:
91,820 Volume:
$12.28 Open:
SLP Latest News
March 03, 2026 07:55:00 am
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
February 09, 2026 06:45:00 pm
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
January 21, 2026 04:05:00 pm
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
SLP Stock Data
$281,347,060
16,298,587
16.67%
64
N/A
Healthcare Providers & Services
Healthcare
US
Research Triangle Park
